protein p54

The non-POU domain-containing octamer-binding protein (NONO, also known as p54nrb) is a multifunctional Drosophila behavior/human splicing (DBHS) family protein that acts as a molecular scaffold to integrate transcriptional regulation, RNA processing, and DNA damage repair (Direct, High; PMID: 34079086, 38493226). In cancer, NONO is frequently upregulated and serves as a potent oncogenic driver by stabilizing key transcription factors, facilitating aberrant RNA splicing, and promoting resistance to chemotherapy and apoptosis (Direct, High; PMID: 35013116, 32724453).

Molecular Mechanisms in RNA Metabolism

NONO regulates the transcriptome through diverse protein-protein and protein-nucleic acid interactions, often forming obligate heterodimers with other DBHS members like SFPQ (PSF) and PSPC1 (Direct, High; PMID: 35886974, 36209820).

• Paraspeckle Assembly: NONO is an essential structural component of paraspeckles, nuclear condensates scaffolded by the long non-coding RNA (lncRNA) NEAT1_2. It binds NEAT1_2 via its RRM1 domain and G-quadruplex motifs to initiate phase-separated organelle formation (Direct, High; PMID: 29932899, 32496517).
• Pre-mRNA Splicing and Processing: NONO facilitates the splicing and maturation of transcripts by binding introns and 5' splice sites (Direct, High; PMID: 12417296, 35910786). In neuroblastoma, it enhances the processing of 5' ends of super-enhancer-associated genes like GATA2 and HAND2 (Direct, High; PMID: 36416237). In glioblastoma, its loss induces GPX1 intron retention, impairing redox homeostasis (Direct, High; PMID: 35910786).
• mRNA Stability: It enhances the stability of various mRNAs, including STAT3 in triple-negative breast cancer (TNBC) and hypoxia-induced genes (e.g., VEGFA, GLUT1) in hepatocellular carcinoma (HCC) (Direct, High; PMID: 34079086).
• IRES-Dependent Translation: NONO acts as an internal ribosome entry site (IRES) trans-acting factor (ITAF) to facilitate cap-independent translation of c-Myc and FGF1 during cellular stress or differentiation (Direct, High; PMID: 28288210, 26332123).
• miRNA Biogenesis: NONO scaffolds RNA-binding proteins and the Microprocessor complex (DROSHA/DGCR8) on NEAT1 to globally enhance pri-miRNA processing (Direct, High; PMID: 28846091).

Regulatory Pathways in Cancer Progression

NONO potentiates oncogenic signaling by acting as a transcriptional co-activator and stabilizer for numerous pathways.

• Hypoxia Signaling: In HCC, NONO interacts with and stabilizes both HIF-1α and HIF-2α complexes, synergistically enhancing the transcription of genes driving angiogenesis and glycolysis (Direct, High; PMID: 34079086).
• Nuclear EGFR and STAT3 Signaling: In TNBC, NONO interacts with nuclear-localized EGFR to recruit CBP/p300 and increase the stability of the EGFR protein (Direct, High; PMID: 35013116). It also directly binds and stabilizes STAT3 RNA and protein, maintaining an oncogenic positive feedback loop (Direct, High; PMID: 32724453).
• Hippo/TAZ Pathway: In glioblastoma (GBM), NONO is required for TAZ to form liquid-liquid phase separation (LLPS) condensates in the nucleus, facilitating TAZ's access to TEAD and enhancers to drive mesenchymal differentiation (Direct, High; PMID: 34716691).
• DNA Damage Repair (DDR): NONO is recruited to DNA double-strand breaks (DSBs), where it promotes non-homologous end joining (NHEJ) (Direct, High; PMID: 39183343). It also relocates to the nucleolus upon etoposide-induced damage to detain aberrant transcripts and prevent R-loop-mediated instability (Direct, High; PMID: 38224452).
• Epigenetic Modulation: NONO recruits the m5C methyltransferase NSUN2 to PTEN pre-mRNA, altering methylation patterns and triggering alternative splicing that inactivates this tumor suppressor (Direct, High; PMID: 40033337).

Clinical Significance and Therapeutic Potential

NONO is a significant prognostic biomarker and a potential therapeutic target across multiple malignancies.

• Prognostic Indicator: High NONO expression independently predicts poor overall survival (OS) and disease-free survival (DFS) in HCC, TNBC, gastric cancer, and melanoma (Direct, High; PMID: 34079086, 35013116, 29773901, 33369124).
• Chemoresistance: NONO confers resistance to sorafenib in HCC and doxorubicin/cisplatin in TNBC and GBM (Direct, High; PMID: 34079086, 32724453, 39183343).
• Therapeutic Targeting:
  • Auranofin: An FDA-approved drug that binds NONO, inducing its degradation and inhibiting downstream targets like GPX1 and STAT3 (Direct, High; PMID: 35910786, 32724453).
  • (R)-SKBG-1: A small-molecule covalent inhibitor that engages C145 of NONO, disrupting its RNA interactions and suppressing protumorigenic networks (Direct, High; PMID: 36864190, 40943463).
  • Immunotherapy: NONO depletion activates the cGAS/STING pathway in TNBC cells due to increased micronuclei and cytoplasmic DNA accumulation, suggesting its inhibition could enhance anti-tumor immunity (Direct, High; PMID: 40943463).

What specific structural domains of the NONO protein mediate its interaction with transcription factors versus its binding to G-quadruplex RNA?

How does NONO-mediated phase separation at DNA damage sites differ from its role in the formation of nuclear paraspeckles?

Which small-molecule inhibitors of NONO, beyond Auranofin, show the most promise for clinical translation in neuroblastoma or TNBC models?

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:32724453 — , VEGFA, GLUT1) in hepatocellular carcinoma (HCC)
  Failed: disease,conclusion — The paper focuses on triple-negative breast cancer (TNBC) and the STAT3 axis, not hepatocellular carcinoma (HCC) or the regulation of VEGFA and GLUT1 in that specific disease context.
• PMID:30824709 — ** DNA Damage Repair (DDR): NONO is recruited to DNA double-strand breaks (DSBs), where it promotes non-homologous ...*
  Failed: conclusion — While the paper discusses NONO in the context of DNA damage, it does not mention or provide data for its role in promoting NHEJ or activating DNA-PK.